Search Results - "Modi, N B"

Refine Results
  1. 1

    Ascorbate prevents placental oxidative stress and enhances birth weight in hypoxic pregnancy in rats by Richter, H. G., Camm, E. J., Modi, B. N., Naeem, F., Cross, C. M., Cindrova‐Davies, T., Spasic‐Boskovic, O., Dunster, C., Mudway, I. S., Kelly, F. J., Burton, G. J., Poston, L., Giussani, D. A.

    Published in The Journal of physiology (01-03-2012)
    “…Key points  •  High‐altitude pregnancy is associated with reduced oxygenation and placental complications, which can affect maternal and fetal outcome…”
    Get full text
    Journal Article
  2. 2

    Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors by DRESSER, M. J, DESAI, D, GIDWANI, S, SEFTEL, A. D, MODI, N. B

    “…Potential pharmacokinetic interactions between dapoxetine, a serotonin transporter inhibitor developed for the treatment of premature ejaculation (PE), and the…”
    Get full text
    Journal Article
  3. 3

    Single- and Multiple-Dose Pharmacokinetics of an Oral Once-a-Day Osmotic Controlled-Release OROS® (methylphenidate HC1) Formulation by Modi, Nishit B., Lindemulder, Betsy, Gupta, Suneel K.

    Published in Journal of clinical pharmacology (01-04-2000)
    “…Methylphenidate is used for the treatment of attention deficit hyperactivity disorder (ADHD). OROS® (methylphenidate HCl) is an osmotic controlled‐release…”
    Get full text
    Journal Article
  4. 4

    TNK-tissue plasminogen activator in acute myocardial infarction : Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial by CANNON, C. P, MCCABE, C. H, LOVE, T. W, BRAUNWALD, E, GIBSON, C. M, GHALI, M, SEQUEIRA, R. F, MCKENDALL, G. R, BREED, J, MODI, N. B, FOX, N. L, TRACY, R. P

    Published in Circulation (New York, N.Y.) (21-01-1997)
    “…TNK-tissue plasminogen activator (TNK-TPA) is a genetically engineered variant of TPA, which in experimental models has a slower plasma clearance and greater…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction by Modi, N B, Eppler, S, Breed, J, Cannon, C P, Braunwald, E, Love, T W

    Published in Thrombosis and haemostasis (01-01-1998)
    “…The rapid clearance of t-PA from plasma requires administration by intravenous (I.V.) infusion. A slower clearing, fibrin-specific rt-PA variant may allow…”
    Get more information
    Journal Article
  7. 7

    Metabolism of [3H]pentosan polysulfate sodium (PPS) in healthy human volunteers by Simon, M., McClanahan, R. H., Shah, J. F., Repko, T., Modi, N. B.

    Published in Xenobiotica (01-08-2005)
    “…Pentosan polysulfate sodium (PPS) is the active ingredient in ELMIRON®, a drug approved for the relief of bladder pain associated with interstitial cystitis…”
    Get full text
    Journal Article
  8. 8

    Dose-Proportional and Stereospecific Pharmacokinetics of Methylphenidate Delivered Using an Osmotic, Controlled-Release Oral Delivery System by Modi, Nishit B., Wang, Bei, Noveck, Robert J., Gupta, Suneel K.

    Published in Journal of clinical pharmacology (01-10-2000)
    “…Methylphenidate hydrochloride (HCl) is frequently used for the treatment of attention deficit/hyperactivity disorder (ADHD). A study was conducted in healthy…”
    Get full text
    Journal Article
  9. 9

    Application of neural networks to pharmacodynamics by Veng-Pedersen, P, Modi, N B

    Published in Journal of pharmaceutical sciences (01-09-1993)
    “…Neural networks (NN) are computational systems implemented in software or hardware that attempt to simulate the neurological processing abilities of biological…”
    Get more information
    Journal Article
  10. 10
  11. 11

    Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction by Modi, Nishit B., Fox, Norma Lynn, Clow, Fong-Wong, Tanswell, Paul, Cannon, Christopher P, Van de Werf, Frans, Braunwald, Eugene

    Published in Journal of clinical pharmacology (01-05-2000)
    “…Tenecteplase is a site‐specific engineered tissue plasminogen activator (t‐PA) variant that can be administered as a single intravenous bolus injection because…”
    Get full text
    Journal Article Conference Proceeding
  12. 12

    The impact of age on clinical outcomes following cardiac resynchronisation therapy by Guha, K., Konstantinou, D., Mantziari, L., Modi, B. N., Chandrasekaran, B., Khalique, Z., McDonagh, T., Sharma, R.

    “…Background Cardiac resynchronisation therapy (CRT) is an established treatment for selected patients with symptomatic left ventricular (LV) systolic…”
    Get full text
    Journal Article
  13. 13

    Effect of Dapoxetine on the Pharmacokinetics and Hemodynamic Effects of Tamsulosin in Men on a Stable Dose of Tamsulosin by Modi, N. B., Kell, S., Aquilina, J., Rivas, D.

    Published in Journal of clinical pharmacology (01-12-2008)
    “…The tolerability of dapoxetine, a short‐acting selective serotonin reuptake inhibitor being developed for premature ejaculation, was evaluated when…”
    Get full text
    Journal Article
  14. 14

    Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered IIb/IIIa Antagonist, in Patients with Acute Coronary Syndrome by Modi, Nishit B., Novotny, William, Reimann, James D., Cannon, Christopher P., Braunwauld, Eugene

    Published in Journal of clinical pharmacology (01-07-1999)
    “…Sibrafiban is a double prodrug that is converted to the inactive single prodrug and to the active IIb/IIIa antagonist following oral administration…”
    Get full text
    Journal Article
  15. 15

    Punch biopsy: A useful adjunct in a rapid diagnosis breast clinic by Modi, B.N, Machin, J.T, Ravichandran, D

    Published in Breast (Edinburgh) (01-04-2010)
    “…Abstract Introduction Triple assessment of breast lesions usually involves the use of core biopsy (CB) or fine needle aspiration cytology (FNAC). Punch Biopsy…”
    Get full text
    Journal Article
  16. 16

    Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep by Widness, J A, Veng-Pedersen, P, Modi, N B, Schmidt, R L, Chestnut, D H

    “…Although erythropoietin (Ep) is considered the primary hormone responsible for erythrocyte production throughout development, the administration of recombinant…”
    Get more information
    Journal Article
  17. 17

    The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats by Zioncheck, T F, Richardson, L, DeGuzman, G G, Modi, N B, Hansen, S E, Godowski, P J

    Published in Endocrinology (Philadelphia) (01-04-1994)
    “…Hepatocyte growth factor (HGF) is a pluripotent mitogen thought to be involved in liver regeneration. It is synthesized as a single chain promitogen and…”
    Get more information
    Journal Article
  18. 18

    Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered GP IIb/IIIa Antagonist, following Coadministration of Aspirin and Heparin by Reimann, James D., Modi, Nishit B., Novotny, William

    Published in Journal of clinical pharmacology (01-05-2000)
    “…Sibrafiban is a double prodrug that is converted to the inactive single prodrug and to the active GP IIb/IIIa antagonist after oral administration. This…”
    Get full text
    Journal Article Conference Proceeding
  19. 19

    Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor by Lin, Y S, Nguyen, C, Mendoza, J L, Escandon, E, Fei, D, Meng, Y G, Modi, N B

    “…Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and in pathological processes such as tumor growth, rheumatoid arthritis, and…”
    Get more information
    Journal Article
  20. 20

    Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form by Refino, C J, Modi, N B, Bullens, S, Pater, C, Lipari, M T, Robarge, K, Blackburn, B, Beresini, M, Weller, T, Steiner, B, Bunting, S

    Published in Thrombosis and haemostasis (01-01-1998)
    “…Ro 44-3888 is a potent and selective antagonist of GP IIb/IIIa. Following I.V. administration to rhesus monkeys, the (mean +/- SD.) clearance, volume of…”
    Get more information
    Journal Article